The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Radiotherapy remains a cornerstone in cancer treatment, used in over 50% of cases. It employs ionizing radiation, primarily X-rays, to target and destroy tumors through direct DNA damage and indirect effects via reactive oxygen species. Despite technological advancements improving precision of the delivered dose to the tumor, radiotherapy faces critical challenges, particularly damage to healthy tissues, which limits the maximum safe dose. Recent years have seen significant improvements in radiation delivery, including advanced imaging for real-time tumor tracking and combinations with immunotherapy. However, the need for innovative strategies to enhance radiotherapy’s therapeutic index remains essential. The radioenhancer NBTXR3 could represent a solution in addressing these limitations. This nanotechnology has been designed to amplify radiotherapy’s effects within tumors without increasing toxicity in non-injected adjacent healthy tissues. Beyond better cancer cell destruction and tumor control, radiotherapy-activated NBTXR3 nanoparticles can also stimulate systemic antitumor immune responses in preclinical models. This review aims to provide a comprehensive analysis of preclinical research on NBTXR3, focusing on its mechanism of action and role in initiating and enhancing antitumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hafnium oxide nanoparticles (NBTXR3/Hensify) represent the most advanced example, demonstrating clinical efficacy in combination with radiotherapy and obtaining regulatory approval for locally advanced soft tissue sarcoma, with ongoing evaluation in additional tumor types [112,113,114,115].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [113]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One important reason is that NBTXR3 has been successfully developed for tumors amenable to direct intratumoral administration, whereas breast cancer is frequently treated following surgical resection or within multimodal treatment pathways that include systemic therapy, limiting opportunities for local nanoparticle delivery and complicating evaluation of biodistribution within residual microscopic”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Immunogenic cell death (ICD) is a form of cell death that triggers an immune response by releasing damage-associated molecular patterns (DAMPs) and tumor antigens, which can activate dendritic cells and other immune cells [36–38].”
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 2×
“Immunogenic cell death (ICD) is a form of cell death that triggers an immune response by releasing damage-associated molecular patterns (DAMPs) and tumor antigens, which can activate dendritic cells and other immune cells [36–38].”
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333 · cited 1×
“Free DNA found in the cytoplasm is a powerful trigger for the cGAS-STING pathway [33, 34].”
Huotari, J., & Helenius, A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.286 · Cited by 2,265 · cited 1×
“Endosomes formed through macropinocytosis usually fuse with lysosomes [19].”
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834 · cited 1×
“Free DNA found in the cytoplasm is a powerful trigger for the cGAS-STING pathway [33, 34].”
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293 · cited 1×
“The resulting immune activation is multifaceted: it enhances antigen presentation, mobilizes natural killer cells, and promotes cytotoxic T lymphocyte activation and differentiation [35].”
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · cited 1×
“These antigens are then taken up by dendritic cells and other antigen-presenting cells, which process and present them to T cells [30, 31].”
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953 · cited 1×
“The release of antigens by dead tumor cells is crucial for the activation of the antitumor immune response [29].”
Cited by
Mateo, B., Patel, K., Murphy, S. V., & Singh, R. (2026) · Nanomaterials · doi:10.3390/nano16080457 · Cited by 2
“Following injection into the tumor, NBTXR3 remains within the tumor throughout a multi-week radiotherapy course (5–7 weeks) so that one injection is enough to achieve dose enhancement for multiple rounds of radiation [32,58].”
Silica-based particles for radiation theranostics
Nakamura, M. (2026) · Chemical Communications · doi:10.1039/d6cc01552b · Cited by 1
Lunca, S., Morarasu, S., & Dimofte, G. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146522 · Cited by 2
Emerging Treatments and Novel Modalities in Head and Neck Cancers
Kirtane, K., Dhar, H., Dcruz, A. K., & Yom, S. S. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516922
Zheng, Z., Zhou, D.-H., Gan, Z.-H., & Yu, Q.-S. (2026) · Chinese Journal of Polymer Science · doi:10.1007/s10118-026-3748-9
Metadata
- Authors
- Bienassis, C., Vivar, O. I., Hu, Y., Da silva, J., Darmon, A., Marill, J., Anesary, N. M., Schmitt, P., Levy, L., Welsh, J., Prezado, Y., Megnin-Chanet, F., & Paris, S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Nanobiotix (France) (FR)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Paris, Sébastien
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-17
- Volume
- 44
- Issue
- 1
- Pages
- 320-320
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC12709859
- OpenAlex
- W4417425991
- Cited by
- 9
- References
- 49
- Citations by year
- 2026: 9
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- NBTXR3, radiotherapy, radiosensitization, nanotechnology, antitumor immunity, DNA damage, reactive oxygen species, radiation toxicity, combination immunotherapy, therapeutic index
- MeSH terms
- Animals, Humans, Neoplasms, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity. https://app.cochat.ai/papers/10.1186/s13046-025-03579-1
- The paper
- Bienassis, C., Vivar, O. I., Hu, Y., Da silva, J., Darmon, A., Marill, J., Anesary, N. M., Schmitt, P., Levy, L., Welsh, J., Prezado, Y., Megnin-Chanet, F., & Paris, S. (2025). The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03579-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.